In this piece, we will look at where Biogen Inc. (NASDAQ:BIIB) ranks on the list. With the 2024 US Presidential Election having come to a close, Wall Street can now focus on the future of ...

Needham sees no near-term catalysts for Biogen The brokerage said it sees Leqembi’s sales projection “likely to continue to be a slow grind, rather than see an inflection point” and said it ...

The two companies have been partnered on Samsung Bioepis for the best part of a decade, successfully bringing six biosimilar copies of biologic drugs to regulatory approval, but Biogen now says it ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

In this piece, we will look at where Biogen Inc. (NASDAQ:BIIB) ranks on the list. With the 2024 US Presidential Election having come to a close, Wall Street can now focus on the future of artificial ...

Sage to abandon development of neurological disorder drug after multiple failures November 20, 2024 The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's ...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Find yourself with a bigger appetite on rest days than after logging your hardest workout of the week? Same. It usually takes me an hour or two to feel hunger after an intense session, and while there ...